Baloxavir vs oseltamivir: reduced utilization and costs in influenza.

Autor:	Neuberger E; Genentech Inc, 1 DNA Way, South San Francisco, CA 94080. Email: edward.neuberger@gmail.com., Wallick C, Chawla D, Castro RC
Jazyk:	angličtina
Zdroj:	The American journal of managed care [Am J Manag Care] 2022 Mar 01; Vol. 28 (3), pp. e88-e95. Date of Electronic Publication: 2022 Mar 01.
DOI:	10.37765/ajmc.2022.88786
Abstrakt:	Objectives: To determine whether baloxavir use is associated with lower health care resource utilization (HCRU) and costs for secondary influenza complications post treatment compared with oseltamivir. Study Design: Retrospective cohort study. Methods: Patients filling a prescription for baloxavir or oseltamivir within 48 hours following an influenza-related outpatient visit were identified in the 2018-2019 influenza season from the US Truven MarketScan Research Databases and propensity matched 1:2 (baloxavir:oseltamivir). Outcomes were assessed 15 and 30 days after antiviral treatment and included all-cause, all respiratory-related, and select respiratory-related (influenza, asthma, chronic obstructive pulmonary disease, or infection) HCRU and costs. Results: The study included 5080 baloxavir-treated and 10,160 matched oseltamivir-treated patients. All-cause emergency department (ED) visits and inpatient hospitalizations were lower in baloxavir-treated patients, with a statistically significant difference in the percentage hospitalized at 30 days (0.3% vs 0.5%; P = .04). ED visits for all or select respiratory-related conditions were significantly reduced with baloxavir (P < .01 for all comparisons). Mean per-patient cost savings at day 30 for all-cause, all respiratory-related, and select respiratory-related conditions were $79, $50, and $51, respectively, despite slightly higher prescription costs for baloxavir. In high-risk patients (baloxavir: n = 1958; oseltamivir: n = 3949), the incidence of ED visits was significantly lower for all respiratory-related and select respiratory-related conditions (P < .01); cost savings with baloxavir in the high-risk cohort were substantially greater than in the overall cohort. Conclusions: Treatment of patients with influenza with single-dose baloxavir was generally associated with lower HCRU and costs post treatment compared with oseltamivir, particularly in high-risk patients.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu